Skip to content

Immunovant, Inc. IMVT Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Merck & Co. logo
Merck & Co.MRK
20M0.0%
Summit Therapeutics logo
Summit TherapeuticsSMMT
IQVIA logo
IQVIAIQV
Incyte logo
IncyteINCY
Moderna logo
ModernaMRNA
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s convertible preferred stock authorized shares?
Immunovant, Inc. (IMVT) reported convertible preferred stock authorized shares of 10M in Q4 2025.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.